Table III.
Association between hormone therapy and survival for 341 lymph node-negative breast cancer patients.
| Mean DFS, years | Mean OS, years | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Hormone therapy | Yes | No | P-value | Yes | No | P-value |
| All patients | 8.3 | 9.3 | 0.003a | 10.2 | 9.4 | 0.002a |
| Menopausal status | ||||||
| Postmenopausal | 9.4 | 8.7 | 0.100 | 10.1 | 9.4 | 0.200 |
| Premenopausal | 9.2 | 8.1 | 0.008a | 10.1 | 8.5 | 0.006a |
| Tumor diameter, cm | ||||||
| ≤2 | 9.4 | 8.7 | 0.050 | 10.1 | 9.5 | 0.020a |
| >2 | 9.0 | 7.9 | 0.040a | 10.1 | 9.0 | 0.030a |
| ER | ||||||
| Positive | 9.6 | 8.6 | 0.010a | 10.1 | 9.5 | 0.004a |
| Negative | 8.9 | 7.8 | 0.070 | 10.1 | 9.0 | 0.200 |
a
P<0.05.
ER, estrogen receptor; DFS, disease-free survival; OS, overall survival.